Published in Inflamm Bowel Dis on February 01, 2005
A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med (2008) 2.42
Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol (2013) 2.13
Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One (2012) 1.66
Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. Trials (2012) 1.49
Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease. Front Pediatr (2017) 1.39
Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis (2010) 1.16
Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr (2008) 1.02
C-reactive protein and disease activity in children with Crohn's disease. Dig Dis Sci (2010) 0.91
Biologics in paediatric Crohn's disease. Gastroenterol Res Pract (2011) 0.78
The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease. Clin Epidemiol (2016) 0.75
Assessing pediatric ileocolonic Crohn's disease activity based on global MR enterography scores. Eur Radiol (2016) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol (2007) 6.19
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension (2009) 3.48
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology (2007) 2.96
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2013) 2.65
A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol (2012) 2.63
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology (2009) 2.09
A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis (2014) 2.09
Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol (2008) 2.09
Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis. J Pediatr Gastroenterol Nutr (2012) 2.05
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol (2006) 2.03
Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr (2005) 1.98
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis (2011) 1.91
Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease. J Pediatr Gastroenterol Nutr (2013) 1.82
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
AGA technical review on perianal Crohn's disease. Gastroenterology (2003) 1.80
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Management of ingested magnets in children. J Pediatr Gastroenterol Nutr (2012) 1.78
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr (2007) 1.74
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 1.70
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics (2006) 1.67
Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One (2012) 1.66
Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr (2004) 1.60
Depression subtypes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2014) 1.57
Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol (2004) 1.53
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol (2011) 1.53
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis (2011) 1.47
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther (2012) 1.45
Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis (2006) 1.43
Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis (2011) 1.42
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2). J Hypertens (2013) 1.42
Predictors of depression in youth with Crohn disease. J Pediatr Gastroenterol Nutr (2014) 1.42
Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology (2002) 1.40
An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc (2012) 1.39
Extraintestinal Hodgkin disease in a young man with Crohn disease treated with multiple immunosuppresive therapies. J Pediatr Gastroenterol Nutr (2013) 1.39
Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network. J Pediatr Gastroenterol Nutr (2016) 1.39
Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci (2002) 1.38
Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol (2009) 1.37
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis (2007) 1.37
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
Tacrolimus-associated eosinophilic gastroenterocolitis in pediatric liver transplant recipients: role of potential food allergies in pathogenesis. Pediatr Transplant (2006) 1.34
Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis (2006) 1.34
Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol (2006) 1.33
The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol (2006) 1.33
Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology (2010) 1.32
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology (2004) 1.32
Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol (2003) 1.29
Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol (2011) 1.29
Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr (2009) 1.26
Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol (2002) 1.26
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry (2007) 1.22
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis (2009) 1.18
Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis (2007) 1.17
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis (2008) 1.17
Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol (2011) 1.16
Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr (2009) 1.15
Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2008) 1.14
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis (2009) 1.14
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol (2010) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis (2009) 1.13